UiPath Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
UiPath wird ein jährliches Gewinn- und Umsatzwachstum von 1.2% bzw. 8.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 20.1% betragen.
Wichtige Informationen
1.2%
Wachstumsrate der Gewinne
12.42%
EPS-Wachstumsrate
| Software Gewinnwachstum | 19.9% |
| Wachstumsrate der Einnahmen | 8.1% |
| Zukünftige Eigenkapitalrendite | 20.08% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 06 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Seeking Alpha • May 06
How UiPath Is A Hidden AI Play
Summary UiPath (PATH) delivered Q4 revenue of $481.11M, up 13.5% Y/Y, with non-GAAP EPS of $0.30 beating expectations. PATH’s agentic automation platform leverages AI, but markets remain unconvinced of accelerated adoption or material upside from these features. High short interest (23.63%) and sector-wide selling pressure have driven PATH’s valuation down, earning it a Hold quant rating. Strong ARR and industry-leading value provide stability, but investors should await clear uptrend or AI-driven sales acceleration before increasing exposure. Read the full article on Seeking Alpha
Narrativ-Update • May 02
PATH: Agentic AI Automation Adoption Will Drive Future ARR Stability
Analysts have trimmed their average price targets on UiPath by several dollars, bringing them into a roughly $12 to $17 range. They cited strong Q4 execution and growing AI driven automation use cases, along with valuation compression across software peers and a need for clearer evidence of sustained AI monetization and net new ARR growth.Narrativ-Update • Apr 18
PATH: Agentic AI Automation And ARR Stability Will Drive Future Upside
Analysts have reduced UiPath's average price target by a few dollars to a roughly mid-teens dollar value. They cite solid Q4 execution and ARR trends, but also point to valuation compression across software peers, along with a need for clearer AI monetization and sustained net new ARR growth.Narrativ-Update • Apr 03
PATH: Agentic AI Automation And ARR Stability Will Support Future Upside
Analysts have nudged the average price target for UiPath slightly lower to around the mid teens in $ terms, trimming expectations on valuation multiples, even as they cite solid Q4 execution, steady ARR trends and growing interest in AI driven automation as key supports for the story. Analyst Commentary Recent research points to a mixed but generally balanced view on UiPath, with most firms trimming price targets while acknowledging solid Q4 execution, resilient ARR and growing interest in AI driven automation.Narrativ-Update • Mar 20
PATH: Agentic AI Automation And Healthcare Solutions Will Support Future Upside
UiPath's updated analyst fair value estimate has shifted from $15.93 to $13.81 as analysts reset price targets across the $12 to $18 range, weighing solid Q4 execution, AI driven automation traction and improving margins against valuation compression, flat to stabilizing net new ARR, and the need for clearer proof of sustained AI monetization. Analyst Commentary Recent research points to a split view on UiPath, with most firms reducing price targets but highlighting both encouraging execution in Q4 and unresolved questions around future growth and valuation.
Neues Narrativ • Mar 12
AI Automation Platform Will Benefit From Long Term Cross System Workflow Complexity
Catalysts About UiPath UiPath provides an end to end automation and AI platform that helps enterprises automate complex workflows across systems, people and software. What are the underlying business or industry changes driving this perspective?
Neues Narrativ • Mar 10
UiPath Inc. (PATH): Agentic AI Pivot and Milestone Profits Set the Stage for Q4 Results
UiPath is currently undergoing a fundamental evolution from a traditional Robotic Process Automation (RPA) provider into a comprehensive "Agentic AI" platform. Trading at $11.60 as of the March 10, 2026, close, the stock dipped 3.1% today as the market maintains a cautious "wait-and-see" stance ahead of its fiscal year-end report.Narrativ-Update • Mar 06
PATH: Healthcare AI Launch And Index Additions Will Support Future Upside
Analysts have trimmed their blended price target for UiPath by about $0.27 to reflect a slightly lower fair value estimate of $15.93, modestly higher discount rate assumptions, and only small tweaks to long term margin and P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see scope for UiPath to reach a price target of US$18, which sits above the trimmed blended fair value estimate of US$15.93, suggesting room for upside if execution aligns with their assumptions.Narrativ-Update • Feb 19
PATH: Index Additions And Buybacks Will Support Future Automation Upside
Analysts have trimmed their UiPath fair value estimate slightly to $16.19 from $16.40, citing mixed expectations around future profitability and valuation multiples, even as revenue assumptions stay relatively steady. Analyst Commentary Street research on UiPath reflects a mix of optimism around sector conditions and caution around how that translates into the company’s valuation and execution over time.Analyseartikel • Feb 06
Some Confidence Is Lacking In UiPath, Inc. (NYSE:PATH) As Shares Slide 30%
UiPath, Inc. ( NYSE:PATH ) shares have had a horrible month, losing 30% after a relatively good period beforehand. The...Narrativ-Update • Feb 05
PATH: AI Software Setup And Index Adds Will Support Automation Outlook
Narrative Update on UiPath UiPath’s implied analyst price target has ticked higher as recent research cites a move from $16 to $18 at one firm and from $12 to $14 at another, with analysts pointing to a generally supportive backdrop for software and ongoing interest in AI related opportunities as key drivers for the updated views. Analyst Commentary Recent research on UiPath centers on how the shares might reflect a mixed backdrop for software, AI related themes, and current valuation levels.Narrativ-Update • Jan 21
PATH: AI Software Setup And Index Adds Will Support Automation Outlook
Narrative update Analysts have nudged their fair value view for UiPath slightly higher, reflecting price target moves such as Barclays lifting its target to US$18 from US$16 and RBC Capital moving to US$14 from US$12, citing a more constructive setup for software and AI exposed names. Analyst Commentary Recent research is broadly constructive, but it also highlights that expectations around AI and software can still be a source of swings in sentiment for UiPath.Narrativ-Update • Jan 07
PATH: AI Trade Enthusiasm And Index Adds Will Shape Automation Outlook
Analysts have inched their fair value estimate for UiPath lower from $16.40 to about $16.27 per share, while still lifting some price targets, such as the move to $14 at RBC Capital. This reflects mixed views as they weigh AI related enthusiasm against updated assumptions for growth, margins and future P/E multiples.Analyseartikel • Dec 23
UiPath Inc.'s (NYSE:PATH) 28% Price Boost Is Out Of Tune With Revenues
The UiPath Inc. ( NYSE:PATH ) share price has done very well over the last month, posting an excellent gain of 28%. The...Narrativ-Update • Dec 21
PATH: AI Partnerships Will Support Automation Gains While Competition Keeps Outlook Balanced
Analysts have modestly increased their fair value estimate for UiPath from approximately $15.93 to $16.40 per share, reflecting a slightly higher long term growth outlook supported by recent price target raises tied to AI driven product enhancements and partnerships, despite ongoing competitive pressures. Analyst Commentary Recent Street commentary reflects a cautiously constructive stance on UiPath, with modest target price increases framed by both optimism around AI driven automation and recognition of intense competitive dynamics.Narrativ-Update • Dec 07
PATH: AI Partnerships Will Drive Automation Hype Yet Leave Shares Vulnerable
UiPath's updated fair value estimate has risen to approximately $15.93 from $13.86, as analysts modestly lift price targets in response to new product launches, strategic partnerships, and expectations that the company can increasingly leverage AI trends, despite a still competitive market. Analyst Commentary Analysts remain measured on UiPath, modestly increasing price targets while keeping neutral ratings as they weigh improving product momentum against a still challenging competitive backdrop.Narrativ-Update • Nov 23
PATH: Partnerships And New AI Offerings Will Shape Automation Leadership Ahead
Analysts have modestly increased their price target for UiPath, raising it from approximately $13.71 to $13.86 per share. They cite recent product updates and ongoing developments in the AI and automation space as supportive factors for the adjustment.Narrativ-Update • Nov 08
PATH: Product Partnerships And Updates Will Shape Future Opportunities In Automation
UiPath's analyst price target has increased to $13 from $12.50, as analysts recognize ongoing product updates and partnerships but remain cautious about the company's growth prospects in a competitive market. Analyst Commentary Recent analyst updates reflect a nuanced perspective on UiPath's future, highlighting both supportive and cautious sentiments about the company's execution and long-term growth prospects.Narrativ-Update • Oct 25
Expanding Automation Partnerships And AI-Powered Agents Will Drive Business Momentum
UiPath’s analyst price target has been revised upward to $13 from $12.50, as analysts cite ongoing product innovation and new partnerships. This comes despite expectations of gradual top-line impact amid ongoing market competition.Narrativ-Update • Oct 10
Agent Builder And Agentic Orchestration Will Expand Market Opportunities
UiPath’s analyst price target has been modestly increased from $13.30 to $13.44, as analysts cite ongoing product and partnership developments. However, they also note persistent competitive pressures in the automation market.Analyseartikel • Oct 07
What UiPath Inc.'s (NYSE:PATH) 26% Share Price Gain Is Not Telling You
UiPath Inc. ( NYSE:PATH ) shareholders would be excited to see that the share price has had a great month, posting a...Narrativ-Update • Sep 06
Agent Builder And Agentic Orchestration Will Expand Market Opportunities
UiPath’s price target has been revised down due to a sharp year-over-year decline in net new ARR and heightened long-term market uncertainty, reflecting a lowered fair value from $14.15 to $13.30. Analyst Commentary Net new annual recurring revenue rose by $30M, but this represents a 30% year-over-year decline.Analyseartikel • Jul 23
When Should You Buy UiPath Inc. (NYSE:PATH)?
UiPath Inc. ( NYSE:PATH ), might not be a large cap stock, but it saw a significant share price rise of 23% in the past...Seeking Alpha • Apr 16
UiPath's Oversold Status Triggers Cheap Buying Opportunity - Maintain Buy
Summary UiPath's kitchen sink FY2026 guidance has triggered growth concerns after the robust 3Y top/bottom-line performance, with it contributing to the massive selloff thus far. This is worsened by the potentially impacted SaaS demand in both federal and commercial end markets, attributed to the DOGE headwinds and higher recessionary risks. Even so, given the still rich Free Cash Flow generation, robust balance sheet, and the growing ARR, we believe that PATH remains well positioned to outperform from current discounted levels. Combined with the recent bullish support at the recent April 2025 bottom of $9.79, we believe that investors may still look forward to a rich upside potential upon reversal in market sentiments. If anything, PATH's recent Peak acquisition is likely to drive renewed growth opportunity, with it likely to "realize increased revenue and margin improvement with the combined technologies." Read the full article on Seeking AlphaSeeking Alpha • Mar 21
The Drop In UiPath Stock Unlocks Long-Term Potential
Summary UiPath’s ARR is set to hit $1.816B in FY26 (+9% YoY), driven by 98% gross and 110% net retention. Cloud ARR surged past $975M (+50% YoY) as enterprise adoption of AI-driven automation accelerates. Profitability improved with a 32% non-GAAP margin, $328M free cash flow, and $1.7B cash (zero debt). Macroeconomic headwinds and public sector delays impacted FY26 revenue guidance, now set at $1.525B–$1.530B. UiPath’s P/S ratio stands at 4.27, near its all-time low, reflecting an attractive valuation relative to revenue growth. Read the full article on Seeking Alpha
Neues Narrativ • Mar 20
Agent Builder And Agentic Orchestration Will Expand Market Opportunities
Strategic partnerships and innovation in automation aim to boost growth through deeper customer relationships and expanded market opportunities.Seeking Alpha • Mar 04
UiPath Stock Is A Buy On The Technical Weakness
Summary The technicals are determined to be highly bearish as signals of weakness are abundant currently. Q3 earnings were mixed and guidance for Q4 was overall weak. However, recent upward EPS revisions show outperformance is likely. The valuation is attractive as the P/S ratio seems too depressed to be justified even as revenue growth continues to slow. Investors should use the technical weakness as a buying opportunity as the fundamental setup is currently net positive. Read the full article on Seeking AlphaSeeking Alpha • Feb 26
UiPath: AI Potential Vs. Margin Reality (Rating Downgrade)
Summary UiPath is evolving beyond robotic process automation into an AI-driven model, expanding its market and potentially unlocking margin expansion by automating complex processes. Both UiPath and Palantir share AI-driven ambitions, but currently operate in distinct markets; overlap could grow if either expands capabilities. Company financials show steady revenue growth, but profitability remains a challenge; improving margins and reducing costs are crucial for re-rating. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 1/31/2029 | 2,054 | 513 | 510 | N/A | 6 |
| 1/31/2028 | 1,906 | 219 | 483 | 497 | 20 |
| 1/31/2027 | 1,758 | 160 | 425 | 435 | 20 |
| 1/31/2026 | 1,611 | 282 | 352 | 371 | N/A |
| 10/31/2025 | 1,553 | 230 | 312 | 335 | N/A |
| 7/31/2025 | 1,497 | 20 | 310 | 335 | N/A |
| 4/30/2025 | 1,451 | -68 | 313 | 340 | N/A |
| 1/31/2025 | 1,430 | -74 | 306 | 321 | N/A |
| 10/31/2024 | 1,411 | -92 | 309 | 320 | N/A |
| 7/31/2024 | 1,383 | -112 | 327 | 334 | N/A |
| 4/30/2024 | 1,354 | -87 | 325 | 332 | N/A |
| 1/31/2024 | 1,308 | -90 | 292 | 299 | N/A |
| 10/31/2023 | 1,211 | -151 | 242 | 247 | N/A |
| 7/31/2023 | 1,148 | -178 | 168 | 178 | N/A |
| 4/30/2023 | 1,103 | -238 | 94 | 110 | N/A |
| 1/31/2023 | 1,059 | -328 | -34 | -10 | N/A |
| 10/31/2022 | 1,040 | -364 | -135 | -110 | N/A |
| 7/31/2022 | 998 | -429 | -132 | -108 | N/A |
| 4/30/2022 | 951 | -408 | -109 | -90 | N/A |
| 1/31/2022 | 892 | -526 | -67 | -55 | N/A |
| 10/31/2021 | 810 | -436 | -42 | -31 | N/A |
| 7/31/2021 | 737 | -384 | -5 | 2 | N/A |
| 4/30/2021 | 681 | -284 | 30 | 36 | N/A |
| 1/31/2021 | 608 | -92 | 26 | 29 | N/A |
| 1/31/2020 | 336 | -520 | -380 | -359 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: PATHDas prognostizierte Gewinnwachstum (1.2% pro Jahr) liegt unter der Sparquote (3.5%).
Ertrag vs. Markt: PATHDie Erträge des Unternehmens (1.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.7% pro Jahr).
Hohe Wachstumserträge: PATHDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: PATHDie Einnahmen des Unternehmens (8.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: PATHDie Einnahmen des Unternehmens (8.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: PATHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (20.1%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/14 12:44 |
| Aktienkurs zum Tagesende | 2026/05/14 00:00 |
| Gewinne | 2026/01/31 |
| Jährliche Einnahmen | 2026/01/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
UiPath, Inc. wird von 31 Analysten beobachtet. 20 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Raimo Lenschow | Barclays |
| William Kingsley Crane | Berenberg |
| Keith Bachman | BMO Capital Markets Equity Research |